טוען...
Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome
BACKGROUND: Antiphospholipid syndrome (APS) is a systemic autoimmune disease characterized by arterial or venous thrombosis (or both) and/or pregnancy morbidity in association with the presence of antiphospholipid antibodies. The prevalence is estimated at 40 to 50 cases per 100,000 people. The most...
שמור ב:
| הוצא לאור ב: | Cochrane Database Syst Rev |
|---|---|
| Main Authors: | , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
John Wiley & Sons, Ltd
2017
|
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6485894/ https://ncbi.nlm.nih.gov/pubmed/28968483 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD012169.pub2 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|